University of Florida Study Finds 81% Cut Opioids With Medical Cannabis

The headline numbers

A University of Florida study reports that 94% of chronic pain patients using medical cannabis experienced relief.

The same study found 81% reduced or stopped taking opioids, according to The Marijuana Herald, which published the summary on Oct. 31, 2026.

That's a striking figure. It also needs context.

What the summary leaves out

The available report doesn't give sample size, study design, authors, or the journal.

It's also unclear whether the 81% refers to all respondents or only those who were taking opioids at baseline, and because CannIntel hasn't reviewed the full paper, we aren't filling those gaps with guesses.

Why self-reported data cuts both ways

Patient-reported outcomes capture real-world use but can't prove cannabis caused the opioid reduction.

Surveys of current patients tend to over-represent people for whom treatment worked. Those who quit the program or saw no benefit often aren't in the sample. A 94% relief rate is exactly what that selection effect can produce.

The view from regulated markets abroad

Regulators in Germany and Canada have weighed similar observational evidence without treating it as proof of efficacy.

• BfArM in Germany ran its own observational data collection on medical cannabis, a design that also leans on patient and physician reports.
• Health Canada regulates medical access under the Cannabis Act and has not framed cannabis as an opioid-replacement therapy.
• The INCB monitors treaty compliance and has long pressed for stronger clinical evidence behind medical claims.

Observational studies move policy debates. Randomized trials move regulators.

What it means for operators and patients

Opioid-reduction data is the most politically useful evidence a medical program can have.

Operators in Florida and other limited-license states can use it in lobbying for qualifying-condition expansions, but patients and physicians should read it as a signal worth testing, not a prescribing guideline. Overstated marketing built on it invites regulatory attention.

Questions to ask of the full paper

Four details will decide how much weight this study deserves.

1. Sample size and recruitment method.
2. Whether opioid use was verified through prescription records or only self-reported.
3. Whether a comparison group existed.
4. Funding sources and conflict disclosures.

For full background on this story, see the CannIntel topic hub on medical cannabis and opioid reduction research.

What to watch next

The decisive test is whether the full methodology survives peer scrutiny.

Watch for publication details from the University of Florida team, including the denominator behind the 81% figure. Until then, treat the number as a lead, not a conclusion.